2016 Fiscal Year Final Research Report
Development of miRNA replacement therapy
| Project/Area Number |
26293088
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
村上 善基 大阪市立大学, 医学(系)研究科(研究院), 准教授 (00397556)
須藤 カツ子 東京医科大学, 医学部, 兼任講師 (50126091)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | miRNA / miR-34 / miR-29 / IPF / Dicer / Ago / 非小細胞性肺がん |
|---|
| Outline of Final Research Achievements |
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and fundamental cell processes such as development, differentiation, proliferation, and apoptosis. Reduced or elevated expression of miRNAs has been implicated in the development of various human diseases, including cancer. Therefore, miRNA replacement therapy represents a promising approach for the treatment of lung cancer. In this project, we developed a 30-nucleotide single-strand RNA, termed “guide hairpin RNA (ghRNA, ghR)”, that has a physiological function similar to miRNA. The ghR caused no innate cytokine response either in vitro or in vivo. In addition, systemic and local injection of ghR-form miR-34a (ghR-34a) suppressed tumor growth in a mouse model of RAS-induced lung cancer. This novel RNA interference (RNAi) technology may provide a novel, safe, and effective nucleic acid drug platform that will increase the clinical usefulness of nucleic acid therapy.
|
| Free Research Field |
人体病理学
|
